Filing Flows › Vanda Pharmaceuticals (VNDA) › Fanapt® revenue
Vanda Pharmaceuticals (VNDA) Fanapt® revenue by quarter
Vanda Pharmaceuticals' Fanapt® revenue was $38.8M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $23.5M (Q1 2025) to $38.8M (Q3 2026).
| Quarter | Fanapt® revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $38.8M | +8% | +24% |
| Q2 2026 | $36.0M | +22% | +23% |
| Q1 2026 | $29.6M | -11% | +26% |
| Q4 2025 | $33.2M | +6% | — |
| Q3 2025 | $31.2M | +7% | — |
| Q2 2025 | $29.3M | +24% | — |
| Q1 2025 | $23.5M | — | — |
Q3 2026 at a glance
Vanda Pharmaceuticals, Q3 2026: revenue $69.8M (+24% year over year), operating margin -33.7%, net loss $22.6M, operating cash flow −$28.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vanda Pharmaceuticals' Fanapt® revenue?
Vanda Pharmaceuticals' Fanapt® revenue was $38.8M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has Vanda Pharmaceuticals' Fanapt® revenue changed?
Over the last 7 quarters it ranged from $23.5M (Q1 2025) to $38.8M (Q3 2026).